- •Global Impact
- •Epidemics and Pandemics
- •Current Situation
- •Individual Impact
- •The Virus
- •Requirements for Success
- •Virology
- •Natural Reservoir + Survival
- •Transmission
- •H5N1: Making Progress
- •Individual Management
- •Epidemic Prophylaxis
- •Exposure Prophylaxis
- •Vaccination
- •Antiviral Drugs
- •Epidemic Treatment
- •Pandemic Prophylaxis
- •Pandemic Treatment
- •Global Management
- •Epidemic Management
- •Pandemic Management
- •Containment
- •Drugs
- •Vaccines
- •Distribution
- •Conclusion
- •Golden Links
- •Interviews
- •References
- •Avian Influenza
- •The Viruses
- •Natural hosts
- •Clinical Presentation
- •Pathology
- •LPAI
- •HPAI
- •Differential Diagnosis
- •Laboratory Diagnosis
- •Collection of Specimens
- •Transport of Specimens
- •Diagnostic Cascades
- •Direct Detection of AIV Infections
- •Indirect Detection of AIV Infections
- •Transmission
- •Transmission between Birds
- •Poultry
- •Humans
- •Economic Consequences
- •Control Measures against HPAI
- •Vaccination
- •Pandemic Risk
- •Conclusion
- •References
- •Structure
- •Haemagglutinin
- •Neuraminidase
- •M2 protein
- •Possible function of NS1
- •Possible function of NS2
- •Replication cycle
- •Adsorption of the virus
- •Entry of the virus
- •Uncoating of the virus
- •Synthesis of viral RNA and viral proteins
- •Shedding of the virus and infectivity
- •References
- •Pathogenesis and Immunology
- •Introduction
- •Pathogenesis
- •Viral entry: How does the virion enter the host?
- •Binding to the host cells
- •Where does the primary replication occur?
- •How does the infection spread in the host?
- •What is the initial host response?
- •Cytokines and fever
- •Respiratory symptoms
- •Cytopathic effects
- •Symptoms of H5N1 infections
- •How is influenza transmitted to others?
- •Immunology
- •The humoral immune response
- •The cellular immune response
- •Conclusion
- •References
- •Pandemic Preparedness
- •Introduction
- •Previous Influenza Pandemics
- •H5N1 Pandemic Threat
- •Influenza Pandemic Preparedness
- •Pandemic Phases
- •Inter-Pandemic Period and Pandemic Alert Period
- •Surveillance
- •Implementation of Laboratory Diagnostic Services
- •Vaccines
- •Antiviral Drugs
- •Drug Stockpiling
- •General Measures
- •Seasonal Influenza Vaccination
- •Political Commitment
- •Legal and Ethical Issues
- •Funding
- •Global Strategy for the Progressive Control of Highly Pathogenic Avian Influenza
- •Pandemic Period
- •Surveillance
- •Treatment and Hospitalisation
- •Human Resources: Healthcare Personnel
- •Geographically Targeted Prophylaxis and Social Distancing Measures
- •Tracing of Symptomatic Cases
- •Border Control
- •Hygiene and Disinfection
- •Risk Communication
- •Conclusions
- •References
- •Introduction
- •Vaccine Development
- •History
- •Yearly Vaccine Production
- •Selection of the yearly vaccine strain
- •Processes involved in vaccine manufacture
- •Production capacity
- •Types of Influenza Vaccine
- •Killed vaccines
- •Live vaccines
- •Vaccines and technology in development
- •Efficacy and Effectiveness
- •Side Effects
- •Recommendation for Use
- •Indications
- •Groups to target
- •Guidelines
- •Contraindications
- •Dosage / use
- •Inactivated vaccine
- •Live attenuated vaccine
- •Companies and Products
- •Strategies for Use of a Limited Influenza Vaccine Supply
- •Antigen sparing methods
- •Rationing methods and controversies
- •Pandemic Vaccine
- •Development
- •Mock vaccines
- •Production capacity
- •Transition
- •Solutions
- •Strategies for expediting the development of a pandemic vaccine
- •Enhance vaccine efficacy
- •Controversies
- •Organising
- •The Ideal World – 2025
- •References
- •Useful reading and listening material
- •Audio
- •Online reading sources
- •Sources
- •Laboratory Findings
- •Introduction
- •Laboratory Diagnosis of Human Influenza
- •Appropriate specimen collection
- •Respiratory specimens
- •Blood specimens
- •Clinical role and value of laboratory diagnosis
- •Patient management
- •Surveillance
- •Laboratory Tests
- •Direct methods
- •Immunofluorescence
- •Enzyme immuno assays or Immunochromatography assays
- •Reverse transcription polymerase chain reaction (RT-PCR)
- •Isolation methods
- •Embryonated egg culture
- •Cell culture
- •Laboratory animals
- •Serology
- •Haemagglutination inhibition (HI)
- •Complement fixation (CF)
- •Ezyme immuno assays (EIA)
- •Indirect immunofluorescence
- •Rapid tests
- •Differential diagnosis of flu-like illness
- •Diagnosis of suspected human infection with an avian influenza virus
- •Introduction
- •Specimen collection
- •Virological diagnostic modalities
- •Other laboratory findings
- •New developments and the future of influenza diagnostics
- •Conclusion
- •Useful Internet sources relating to Influenza Diagnosis
- •References
- •Clinical Presentation
- •Uncomplicated Human Influenza
- •Complications of Human Influenza
- •Secondary Bacterial Pneumonia
- •Primary Viral Pneumonia
- •Mixed Viral and Bacterial Pneumonia
- •Exacerbation of Chronic Pulmonary Disease
- •Croup
- •Failure of Recovery
- •Myositis
- •Cardiac Complications
- •Toxic Shock Syndrome
- •Reye’s Syndrome
- •Complications in HIV-infected patients
- •Avian Influenza Virus Infections in Humans
- •Presentation
- •Clinical Course
- •References
- •Treatment and Prophylaxis
- •Introduction
- •Antiviral Drugs
- •Neuraminidase Inhibitors
- •Indications for the Use of Neuraminidase Inhibitors
- •M2 Ion Channel Inhibitors
- •Indications for the Use of M2 Inhibitors
- •Treatment of “Classic” Human Influenza
- •Antiviral Treatment
- •Antiviral Prophylaxis
- •Special Situations
- •Children
- •Impaired Renal Function
- •Impaired Liver Function
- •Seizure Disorders
- •Pregnancy
- •Treatment of Human H5N1 Influenza
- •Transmission Prophylaxis
- •General Infection Control Measures
- •Special Infection Control Measures
- •Contact Tracing
- •Discharge policy
- •Global Pandemic Prophylaxis
- •Conclusion
- •References
- •Drug Profiles
- •Amantadine
- •Pharmacokinetics
- •Toxicity
- •Efficacy
- •Resistance
- •Drug Interactions
- •Recommendations for Use
- •Warnings
- •Summary
- •References
- •Oseltamivir
- •Introduction
- •Structure
- •Pharmacokinetics
- •Toxicity
- •Efficacy
- •Treatment
- •Prophylaxis
- •Selected Patient Populations
- •Efficacy against Avian Influenza H5N1
- •Efficacy against the 1918 Influenza Strain
- •Resistance
- •Drug Interactions
- •Recommendations for Use
- •Summary
- •References
- •Rimantadine
- •Introduction
- •Structure
- •Pharmacokinetics
- •Toxicity
- •Efficacy
- •Treatment
- •Prophylaxis
- •Resistance
- •Drug Interactions
- •Recommendations for Use
- •Adults
- •Children
- •Warnings
- •Summary
- •References
- •Zanamivir
- •Introduction
- •Structure
- •Pharmacokinetics
- •Toxicity
- •Efficacy
- •Treatment
- •Prophylaxis
- •Children
- •Special Situations
- •Avian Influenza Strains
- •Resistance
- •Drug Interactions
- •Recommendations for Use
- •Dosage
- •Summary
- •References
Antiviral Drugs 173
M2 Ion Channel Inhibitors
Amantadine and rimantadine are tricyclic symmetric adamantanamines. In the 1960s it was discovered that they inhibited strains of influenza (Stephenson 2001). They are active only against influenza A virus (influenza B does not possess an M2 protein), have more side effects than neuraminidase inhibitors, and may select for readily transmissible drug-resistant viruses.
M2 inhibitors block an ion channel formed by the M2 protein that spans the viral membrane (Hay 1985, Sugrue 1991) and is required for viral uncoating (for more details see the Drugs chapter). Both drugs are effective as treatment if started within 24 hours of illness onset, reducing fever and symptoms by 1–2 days (Wingfield 1969, Smorodintsev 1970, van Voris 1981).
Daily prophylaxis during an influenza season reduces infection rates by 50–90 % (Dawkins 1968, Dolin 1982, Clover 1986). Post-exposure prophylaxis of households seems problematic, though. In one study, rimantadine was ineffective in protecting household members from influenza A infection (Hayden 1989).
Gastrointestinal symptoms are the major side effects associated with amantadine and rimantadine. In addition, amantadine has a wide range of toxicity which may be in part attributable to the anticholinergic effects of the drug. In addition, minor reversible CNS side effects may occur during a 5-day treatment in up to one third of patients (van Voris 1981). The same frequency of side effects was found when the drug was tested in young healthy volunteers over a four-week period. Among 44 individuals, side effects (dizziness, nervousness, and insomnia) were well tolerated by most subjects, but 6 volunteers discontinued amantadine because of marked complaints. Cessation of side effects occurred in more than half of those continuing amantadine. 16 volunteers had decreased performance in sustained attention tasks (Bryson 1980). When studied in 450 volunteers during an outbreak of influenza A, the prophylactic effects of rimantadine and amantadine were comparable. Influ- enza-like illness occurred in 14 % of the rimantadine group and in 9 % of the amantadine group (Dolin 1982). Withdrawal from the study because of central nervous system side effects was more frequent in the amantadine (13 %) than in the rimantadine group (6 %).
The potential for drug interactions is greater for amantadine, especially when coadministered with central nervous system stimulants. Agents with anticholinergic properties may potentiate the anticholinergic-like side effects of amantadine. For more details see the chapter, “Drugs”.
Point mutations in the M gene lead to amino acid changes in the transmembrane region of the M2 protein and may confer high-level resistance to amantadine. The genetic basis for resistance appears to be single amino acid substitutions at positions 26, 27, 30, 31 or 34 in the transmembrane portion of the M2 ion channel (Hay 1985). The mutants are as virulent and transmissible as the wild-type virus. In an avian model, they were also genetically stable, showing no reversion to the wildtype after six passages in birds over a period of greater than 20 days (Bean 1989). Such strains may develop in up to one third of patients treated with amantadine or rimantadine; in immunocompromised individuals the percentage may even be higher (Englund 1998). Drug-resistant influenza A virus (H3N2) can be obtained from rimantadine-treated children and adults as early as 2 days after starting treatment (Hayden 1991). Some H5N1 strains which have been associated with human